



**AUSTRALIA
Biotech
Invest 2016**
Connecting Capital with Innovation
www.australiabiotechinvest.com.au

26 - 27
October
2016

Host Industry Body Host State Partner Major Partner

AusBiotech
AUSTRALIA BIOTECHNOLOGY ORGANISATION

MELBOURNE
Victoria
Australia

100^{cs}
Just getting started

Melbourne Convention
Centre, Victoria, Australia

Company Profile

GI Therapies Pty Ltd

GI Therapies was established in 2012 to commercialise technology developed at the Murdoch Childrens Research Institute to treat gastro motility disorders in children and adults.

Currently there is a large unmet medical need for safe and effective therapies to treat chronic constipation, Irritable Bowel Syndrome and other GI motility problems.

The Company's technology uses a non invasive medical device with no known side effects. It is used for one hour per day for 1-3 months. Clinical data to date indicates that around 50-60% of patients responds to the treatment. In contrast, the newer approved drugs have response rates between 20-45%.

Marketing approval in Europe is anticipated in Q4 2016 with Australian approval to follow in early 2017. Pivotal clinical trials are planned to commence in 2017 in the US with a view to secure marketing approval in 2018.